Pub Date : 2018-05-14eCollection Date: 2018-01-01DOI: 10.1155/2018/9218595
Ashini Weerasinghe, Courtney R Smith, Vicky Majpruz, Anjali Pandya, Kristina M Blackmore, Claire M B Holloway, Roanne Segal-Nadlere, Cathy Paroschy Harris, Ashley Hendry, Amanda Hey, Anat Kornecki, George Lougheed, Barbara-Anne Maier, Patricia Marchand, David McCready, Carol Rand, Simon Raphael, Neelu Sehgal, Anna M Chiarelli
Objective: Medical chart abstraction is the gold standard for collecting breast cancer treatment data for monitoring and research. A less costly alternative is the use of administrative databases. This study will evaluate administrative data in comparison to medical charts for breast cancer treatment information.
Study design and setting: A retrospective cohort design identified 2,401 women in the Ontario Breast Screening Program diagnosed with invasive breast cancer from 2006 to 2009. Treatment data were obtained from the Activity Level Reporting and Canadian Institute of Health Information databases. Medical charts were abstracted at cancer centres. Sensitivity, specificity, positive and negative predictive value, and kappa were calculated for receipt and type of treatment, and agreement was assessed for dates. Logistic regression evaluated factors influencing agreement.
Results: Sensitivity and specificity for receipt of radiotherapy (92.0%, 99.3%), chemotherapy (77.7%, 99.2%), and surgery (95.8%, 100%) were high but decreased slightly for specific radiotherapy anatomic locations, chemotherapy protocols, and surgeries. Agreement increased by radiotherapy year (trend test, p < 0.0001). Stage II/III compared to stage I cancer decreased odds of agreement for chemotherapy (OR = 0.66, 95% CI: 0.48-0.91) and increased agreement for partial mastectomy (OR = 3.36, 95% CI: 2.27-4.99). Exact agreement in treatment dates varied from 83.0% to 96.5%.
Conclusion: Administrative data can be accurately utilized for future breast cancer treatment studies.
{"title":"Validity of Administrative Databases in Comparison to Medical Charts for Breast Cancer Treatment Data.","authors":"Ashini Weerasinghe, Courtney R Smith, Vicky Majpruz, Anjali Pandya, Kristina M Blackmore, Claire M B Holloway, Roanne Segal-Nadlere, Cathy Paroschy Harris, Ashley Hendry, Amanda Hey, Anat Kornecki, George Lougheed, Barbara-Anne Maier, Patricia Marchand, David McCready, Carol Rand, Simon Raphael, Neelu Sehgal, Anna M Chiarelli","doi":"10.1155/2018/9218595","DOIUrl":"https://doi.org/10.1155/2018/9218595","url":null,"abstract":"<p><strong>Objective: </strong>Medical chart abstraction is the gold standard for collecting breast cancer treatment data for monitoring and research. A less costly alternative is the use of administrative databases. This study will evaluate administrative data in comparison to medical charts for breast cancer treatment information.</p><p><strong>Study design and setting: </strong>A retrospective cohort design identified 2,401 women in the Ontario Breast Screening Program diagnosed with invasive breast cancer from 2006 to 2009. Treatment data were obtained from the Activity Level Reporting and Canadian Institute of Health Information databases. Medical charts were abstracted at cancer centres. Sensitivity, specificity, positive and negative predictive value, and kappa were calculated for receipt and type of treatment, and agreement was assessed for dates. Logistic regression evaluated factors influencing agreement.</p><p><strong>Results: </strong>Sensitivity and specificity for receipt of radiotherapy (92.0%, 99.3%), chemotherapy (77.7%, 99.2%), and surgery (95.8%, 100%) were high but decreased slightly for specific radiotherapy anatomic locations, chemotherapy protocols, and surgeries. Agreement increased by radiotherapy year (trend test, <i>p</i> < 0.0001). Stage II/III compared to stage I cancer decreased odds of agreement for chemotherapy (OR = 0.66, 95% CI: 0.48-0.91) and increased agreement for partial mastectomy (OR = 3.36, 95% CI: 2.27-4.99). Exact agreement in treatment dates varied from 83.0% to 96.5%.</p><p><strong>Conclusion: </strong>Administrative data can be accurately utilized for future breast cancer treatment studies.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2018-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/9218595","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36189479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim. To assess the effect of various lifestyle risk factors on the risk of salivary gland cancer in Canada using data from a population-based case-control study. Methods. Data from a population-based case-control study of 132 incident cases of salivary gland cancer and 3076 population controls were collected through self-administered questionnaire and analysed using unconditional logistic regression. Results. Four or more servings/week of processed meat product was associated with an adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) of 1.62 (1.02–2.58). Nonsignificantly increased ORs were also related to obesity, >7 drinks/week of alcohol consumption, and occupational exposure to radiation. Furthermore, nonsignificantly decreased ORs were found to be associated with high education level (>12 years) (OR = 0.65), high consumption of spinach/squash (OR = 0.62) and all vegetables/vegetable juices (OR = 0.75), and >30 sessions/month of recreational physical activity (OR = 0.78). Conclusions. This study suggests positive associations with consumption of processed meat, smoking, obesity, alcohol drinking, and occupational exposure to radiation as well as negative associations with higher education, consumption of spinach/squash, and physical activity, which suggest a role of lifestyle factors in the etiology of salivary gland cancer. However, these findings were based on small number of cases and were nonsignificant. Further larger studies are warranted to confirm our findings.
{"title":"A Case-Control Study of Risk Factors for Salivary Gland Cancer in Canada","authors":"S. Pan, M. de Groh, H. Morrison","doi":"10.1155/2017/4909214","DOIUrl":"https://doi.org/10.1155/2017/4909214","url":null,"abstract":"Aim. To assess the effect of various lifestyle risk factors on the risk of salivary gland cancer in Canada using data from a population-based case-control study. Methods. Data from a population-based case-control study of 132 incident cases of salivary gland cancer and 3076 population controls were collected through self-administered questionnaire and analysed using unconditional logistic regression. Results. Four or more servings/week of processed meat product was associated with an adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) of 1.62 (1.02–2.58). Nonsignificantly increased ORs were also related to obesity, >7 drinks/week of alcohol consumption, and occupational exposure to radiation. Furthermore, nonsignificantly decreased ORs were found to be associated with high education level (>12 years) (OR = 0.65), high consumption of spinach/squash (OR = 0.62) and all vegetables/vegetable juices (OR = 0.75), and >30 sessions/month of recreational physical activity (OR = 0.78). Conclusions. This study suggests positive associations with consumption of processed meat, smoking, obesity, alcohol drinking, and occupational exposure to radiation as well as negative associations with higher education, consumption of spinach/squash, and physical activity, which suggest a role of lifestyle factors in the etiology of salivary gland cancer. However, these findings were based on small number of cases and were nonsignificant. Further larger studies are warranted to confirm our findings.","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4909214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41268266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-02-22DOI: 10.1155/2017/8312064
Subhojit Dey, Preet K Dhillon, Preetha Rajaraman
Cancer is a rising problem across the world with a 33% increase in global cases of cancer between 2005 and 2015 [1]. The increase has been maximum in countries with the lowest development [1]. While LMICs bear a major share of the burden of cancer [1–3], very few LMICs have a comprehensive cancer prevention strategy in place.This leads to a high proportion of patients presenting at tertiary care centres at late stages of cancer, when treatment is most difficult and costly and survival is poor [4]. In the absence of adequate treatment capacity in most LMICs, patients presenting at later stages significantly increase the burden of disease. Lack of palliative care [5] compounds this situation further resulting in anunfortunate scenariowhere a diagnosis of cancer is equated with death in most LMICs. With reducing levels of infectious diseases and rising life expectancies, LMICs are recognizing that cancer needs to become a health priority. However, the essential steps required to prevent cancer and avoid the later consequences are still lacking emphasis. With the above scenario in mind, we had issued a call for papers that focused on cancer prevention in LMICs. Overall, it was observed that research on cancer and especially cancer prevention in LMICs was limited [6]. Among the cancer research that is being done in LMICs, a lot of research is not of good quality. Also, most of the focus is currently on building capacity and conducting research related to cancer treatment, and cancer prevention takes a back seat, for cancer prevention requires not only facilities and human resources on the health system side but also awareness and the will and ability to pay for preventive services on the population side. Given the situation in most LMICs, both sides fall short of reaching a point where cancer prevention can be a realistic scenario. Regarding this, it is important to note the recommendations of the Breast Health Global Initiative (BHGI) which has created guidelines for breast cancer prevention while considering the economic situation of a particular nation [7]. We need to focus more on cancer prevention in LMICs, and while the job of the health providers and researchers including thosewho contributed to this special issue is commendable, there is immense scope for more to be done.
{"title":"Cancer Prevention in Low- and Middle-Income Countries.","authors":"Subhojit Dey, Preet K Dhillon, Preetha Rajaraman","doi":"10.1155/2017/8312064","DOIUrl":"https://doi.org/10.1155/2017/8312064","url":null,"abstract":"Cancer is a rising problem across the world with a 33% increase in global cases of cancer between 2005 and 2015 [1]. The increase has been maximum in countries with the lowest development [1]. While LMICs bear a major share of the burden of cancer [1–3], very few LMICs have a comprehensive cancer prevention strategy in place.This leads to a high proportion of patients presenting at tertiary care centres at late stages of cancer, when treatment is most difficult and costly and survival is poor [4]. In the absence of adequate treatment capacity in most LMICs, patients presenting at later stages significantly increase the burden of disease. Lack of palliative care [5] compounds this situation further resulting in anunfortunate scenariowhere a diagnosis of cancer is equated with death in most LMICs. With reducing levels of infectious diseases and rising life expectancies, LMICs are recognizing that cancer needs to become a health priority. However, the essential steps required to prevent cancer and avoid the later consequences are still lacking emphasis. With the above scenario in mind, we had issued a call for papers that focused on cancer prevention in LMICs. Overall, it was observed that research on cancer and especially cancer prevention in LMICs was limited [6]. Among the cancer research that is being done in LMICs, a lot of research is not of good quality. Also, most of the focus is currently on building capacity and conducting research related to cancer treatment, and cancer prevention takes a back seat, for cancer prevention requires not only facilities and human resources on the health system side but also awareness and the will and ability to pay for preventive services on the population side. Given the situation in most LMICs, both sides fall short of reaching a point where cancer prevention can be a realistic scenario. Regarding this, it is important to note the recommendations of the Breast Health Global Initiative (BHGI) which has created guidelines for breast cancer prevention while considering the economic situation of a particular nation [7]. We need to focus more on cancer prevention in LMICs, and while the job of the health providers and researchers including thosewho contributed to this special issue is commendable, there is immense scope for more to be done.","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/8312064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34837097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-08-15DOI: 10.1155/2017/7574946
Ryan A Denu, John M Hampton, Adam Currey, Roger T Anderson, Rosemary D Cress, Steven T Fleming, Joseph Lipscomb, Xiao-Cheng Wu, J Frank Wilson, Amy Trentham-Dietz
Inflammatory breast cancer (IBC) is a rare yet aggressive form of breast cancer. We examined differences in patient demographics and outcomes in IBC compared to locally advanced breast cancer (LABC) and all other breast cancer patients from the Breast and Prostate Cancer Data Quality and Patterns of Care Study (POC-BP), containing information from cancer registries in seven states. Out of 7,624 cases of invasive carcinoma, IBC and LABC accounted for 2.2% (N = 170) and 4.9% (N = 375), respectively. IBC patients were more likely to have a higher number (P = 0.03) and severity (P = 0.01) of comorbidities than other breast cancer patients. Among IBC patients, a higher percentage of patients with metastatic disease versus nonmetastatic disease were black, on Medicaid, and from areas of higher poverty and more urban areas. Black and Hispanic IBC patients had worse overall and breast cancer-specific survival than white patients; moreover, IBC patients with Medicaid, patients from urban areas, and patients from areas of higher poverty and lower education had worse outcomes. These data highlight the effects of disparities in race and socioeconomic status on the incidence of IBC as well as IBC outcomes. Further work is needed to reveal the causes behind these disparities and methods to improve IBC outcomes.
{"title":"Racial and Socioeconomic Disparities Are More Pronounced in Inflammatory Breast Cancer Than Other Breast Cancers.","authors":"Ryan A Denu, John M Hampton, Adam Currey, Roger T Anderson, Rosemary D Cress, Steven T Fleming, Joseph Lipscomb, Xiao-Cheng Wu, J Frank Wilson, Amy Trentham-Dietz","doi":"10.1155/2017/7574946","DOIUrl":"https://doi.org/10.1155/2017/7574946","url":null,"abstract":"<p><p>Inflammatory breast cancer (IBC) is a rare yet aggressive form of breast cancer. We examined differences in patient demographics and outcomes in IBC compared to locally advanced breast cancer (LABC) and all other breast cancer patients from the Breast and Prostate Cancer Data Quality and Patterns of Care Study (POC-BP), containing information from cancer registries in seven states. Out of 7,624 cases of invasive carcinoma, IBC and LABC accounted for 2.2% (<i>N</i> = 170) and 4.9% (<i>N</i> = 375), respectively. IBC patients were more likely to have a higher number (<i>P</i> = 0.03) and severity (<i>P</i> = 0.01) of comorbidities than other breast cancer patients. Among IBC patients, a higher percentage of patients with metastatic disease versus nonmetastatic disease were black, on Medicaid, and from areas of higher poverty and more urban areas. Black and Hispanic IBC patients had worse overall and breast cancer-specific survival than white patients; moreover, IBC patients with Medicaid, patients from urban areas, and patients from areas of higher poverty and lower education had worse outcomes. These data highlight the effects of disparities in race and socioeconomic status on the incidence of IBC as well as IBC outcomes. Further work is needed to reveal the causes behind these disparities and methods to improve IBC outcomes.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/7574946","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35397869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-04-10DOI: 10.1155/2017/4354592
Emily Boevers, Bradley D McDowell, Sarah L Mott, Anna M Button, Charles F Lynch
Objectives. The study objective was to determine how insurance status relates to treatment receipt and overall survival for patients with early-stage pancreatic exocrine carcinoma. Methods. SEER data were evaluated for 17,234 patients diagnosed with Stage I/II pancreatic exocrine carcinoma. Multivariate regression models controlled for personal characteristics to determine whether insurance status was independently associated with overall survival and receipt of radiation/surgery. Results. Odds of receiving radiation were 1.50 and 1.75 times higher for insured patients compared to Medicaid and uninsured patients, respectively (p < 0.01). Insured patients had 1.68 and 1.57 times increased odds of receiving surgery compared to Medicaid and uninsured patients (p < 0.01). Risk of death was 1.33 times greater (p < 0.01) in Medicaid patients compared to insured patients; when further adjusted for treatment, the risk of death was attenuated but remained significant (HR = 1.16, p < 0.01). Risk of death was 1.16 times higher for uninsured patients compared to insured patients (p = 0.02); when further adjusted for treatment, the risk of death was no longer significant (HR = 1.01, p = 0.83). Conclusions. Uninsured and Medicaid-insured patients experience lower treatment rates compared to patients who have other insurances. The increased likelihood of treatment appears to explain the insured group's survival advantage.
目标。研究的目的是确定保险状况与早期胰腺外分泌癌患者的治疗接受和总生存期之间的关系。方法。对17234例I/II期胰腺外分泌癌患者的SEER数据进行了评估。多变量回归模型控制了个人特征,以确定保险状况是否与总体生存和接受放射/手术独立相关。结果。参保患者接受放疗的几率分别是参保患者和未参保患者的1.50倍和1.75倍(p < 0.01)。参保患者接受手术的几率是未参保患者的1.68倍和1.57倍(p < 0.01)。医疗补助患者的死亡风险是参保患者的1.33倍(p < 0.01);进一步调整治疗后,死亡风险有所降低,但仍有显著性差异(HR = 1.16, p < 0.01)。未参保患者的死亡风险是参保患者的1.16倍(p = 0.02);进一步调整治疗后,死亡风险不再显著(HR = 1.01, p = 0.83)。结论。与有其他保险的患者相比,没有保险和有医疗补助的患者的治疗率更低。治疗可能性的增加似乎解释了投保组的生存优势。
{"title":"Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma.","authors":"Emily Boevers, Bradley D McDowell, Sarah L Mott, Anna M Button, Charles F Lynch","doi":"10.1155/2017/4354592","DOIUrl":"https://doi.org/10.1155/2017/4354592","url":null,"abstract":"<p><p><i>Objectives</i>. The study objective was to determine how insurance status relates to treatment receipt and overall survival for patients with early-stage pancreatic exocrine carcinoma. <i>Methods</i>. SEER data were evaluated for 17,234 patients diagnosed with Stage I/II pancreatic exocrine carcinoma. Multivariate regression models controlled for personal characteristics to determine whether insurance status was independently associated with overall survival and receipt of radiation/surgery. <i>Results</i>. Odds of receiving radiation were 1.50 and 1.75 times higher for insured patients compared to Medicaid and uninsured patients, respectively (<i>p</i> < 0.01). Insured patients had 1.68 and 1.57 times increased odds of receiving surgery compared to Medicaid and uninsured patients (<i>p</i> < 0.01). Risk of death was 1.33 times greater (<i>p</i> < 0.01) in Medicaid patients compared to insured patients; when further adjusted for treatment, the risk of death was attenuated but remained significant (HR = 1.16, <i>p</i> < 0.01). Risk of death was 1.16 times higher for uninsured patients compared to insured patients (<i>p</i> = 0.02); when further adjusted for treatment, the risk of death was no longer significant (HR = 1.01, <i>p</i> = 0.83). <i>Conclusions</i>. Uninsured and Medicaid-insured patients experience lower treatment rates compared to patients who have other insurances. The increased likelihood of treatment appears to explain the insured group's survival advantage.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4354592","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34980740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-04-06DOI: 10.1155/2017/2705860
Nayha Chopra-Tandon, Haotian Wu, Kathleen F Arcaro, Susan R Sturgeon
It is not yet clear whether white blood cell DNA global methylation is associated with breast cancer risk. In this review we examine the relationships between multiple breast cancer risk factors and three markers of global DNA methylation: LINE-1, 5-mdC, and Alu. A literature search was conducted using Pubmed up to April 1, 2016, using combinations of relevant outcomes such as "WBC methylation," "blood methylation," "blood LINE-1 methylation," and a comprehensive list of known and suspected breast cancer risk factors. Overall, the vast majority of reports in the literature have focused on LINE-1. There was reasonably consistent evidence across the studies examined that males have higher levels of LINE-1 methylation in WBC DNA than females. None of the other demographic, lifestyle, dietary, or health condition risk factors were consistently associated with LINE-1 DNA methylation across studies. With the possible exception of sex, there was also little evidence that the wide range of breast cancer risk factors we examined were associated with either of the other two global DNA methylation markers: 5-mdC and Alu. One possible implication of the observed lack of association between global WBC DNA methylation and known breast cancer risk factors is that the association between global WBC DNA methylation and breast cancer, if it exists, is due to a disease effect.
{"title":"Relationships between Global DNA Methylation in Circulating White Blood Cells and Breast Cancer Risk Factors.","authors":"Nayha Chopra-Tandon, Haotian Wu, Kathleen F Arcaro, Susan R Sturgeon","doi":"10.1155/2017/2705860","DOIUrl":"https://doi.org/10.1155/2017/2705860","url":null,"abstract":"<p><p>It is not yet clear whether white blood cell DNA global methylation is associated with breast cancer risk. In this review we examine the relationships between multiple breast cancer risk factors and three markers of global DNA methylation: <i>LINE-1</i>, 5-mdC, and <i>Alu</i>. A literature search was conducted using Pubmed up to April 1, 2016, using combinations of relevant outcomes such as \"WBC methylation,\" \"blood methylation,\" \"blood <i>LINE-1</i> methylation,\" and a comprehensive list of known and suspected breast cancer risk factors. Overall, the vast majority of reports in the literature have focused on <i>LINE-1</i>. There was reasonably consistent evidence across the studies examined that males have higher levels of <i>LINE-1</i> methylation in WBC DNA than females. None of the other demographic, lifestyle, dietary, or health condition risk factors were consistently associated with <i>LINE-1</i> DNA methylation across studies. With the possible exception of sex, there was also little evidence that the wide range of breast cancer risk factors we examined were associated with either of the other two global DNA methylation markers: 5-mdC and <i>Alu</i>. One possible implication of the observed lack of association between global WBC DNA methylation and known breast cancer risk factors is that the association between global WBC DNA methylation and breast cancer, if it exists, is due to a disease effect.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/2705860","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34979471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-06-28DOI: 10.1155/2017/6170290
Nora Berois, Diego Touya, Luis Ubillos, Bernardo Bertoni, Eduardo Osinaga, Mario Varangot
Background: Incorporation of molecular analysis of the epidermal growth factor receptor (EGFR) gene into routine clinical practice represents a milestone for personalized therapy of the non-small-cell lung cancer (NSCLC). However, the genetic testing of EGFR mutations has not yet become a routine clinical practice in developing countries. In view of different prevalence of such mutations among different ethnicities and geographic regions, as well as the limited existing data from Latin America, our aim was to study the frequency of major types of activating mutations of the EGFR gene in NSCLC patients from Uruguay.
Methods: We examined EGFR mutations in exons 18 through 21 in 289 NSCLC Uruguayan patients by PCR-direct sequencing.
Results: EGFR mutations were detected in 53 of the 289 (18.3%) patients, more frequently in women (23.4%) than in men (14.5%). The distribution by exon was similar to that generally reported in the literature.
Conclusions: This first epidemiological study of EGFR mutations in Uruguay reveals a wide spectrum of mutations and an overall prevalence of 18.3%. The background ethnic structure of the Uruguayan population could play an important role in explaining our findings.
{"title":"Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.","authors":"Nora Berois, Diego Touya, Luis Ubillos, Bernardo Bertoni, Eduardo Osinaga, Mario Varangot","doi":"10.1155/2017/6170290","DOIUrl":"https://doi.org/10.1155/2017/6170290","url":null,"abstract":"<p><strong>Background: </strong>Incorporation of molecular analysis of the epidermal growth factor receptor (EGFR) gene into routine clinical practice represents a milestone for personalized therapy of the non-small-cell lung cancer (NSCLC). However, the genetic testing of EGFR mutations has not yet become a routine clinical practice in developing countries. In view of different prevalence of such mutations among different ethnicities and geographic regions, as well as the limited existing data from Latin America, our aim was to study the frequency of major types of activating mutations of the EGFR gene in NSCLC patients from Uruguay.</p><p><strong>Methods: </strong>We examined EGFR mutations in exons 18 through 21 in 289 NSCLC Uruguayan patients by PCR-direct sequencing.</p><p><strong>Results: </strong>EGFR mutations were detected in 53 of the 289 (18.3%) patients, more frequently in women (23.4%) than in men (14.5%). The distribution by exon was similar to that generally reported in the literature.</p><p><strong>Conclusions: </strong>This first epidemiological study of EGFR mutations in Uruguay reveals a wide spectrum of mutations and an overall prevalence of 18.3%. The background ethnic structure of the Uruguayan population could play an important role in explaining our findings.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/6170290","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35199143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-06-18DOI: 10.1155/2017/8418904
Valerie M Harvey, Clinton W Enos, Jarvis T Chen, Hadiza Galadima, Karl Eschbach
Background: Hispanics diagnosed with cutaneous melanoma are more likely to present at advanced stages but the reasons for this are unknown. We identify census tracts at high risk for late stage melanoma diagnosis (LSMD) and examine the contextual predictors of LSMD in California, Texas, and Florida.
Methods: We conducted a cross-sectional study using geocoded state cancer registry data. Using hierarchical multilevel logistic regression models we estimated ORs and 95% confidence intervals for the impact of socioeconomic, Hispanic ethnic concentration, index of dissimilarity, and health resource availability measures on LSMD.
Results: We identified 12,493 cases. In California, late stage cases were significantly more likely to reside within census tracts composed mostly of Hispanics and immigrants. In Texas, LSMD was associated with residence in areas of socioeconomic deprivation and a higher proportion of immigrants. In Florida, living in areas of low education attainment, high levels of poverty, and a high percentage of Hispanic residents was significantly associated with LSMD. Residential segregation did not independently affect LSMD.
Conclusion: The influence of contextual predictors on LSMD varied in magnitude and strength by state, highlighting both the cosegregation of social adversity and poverty and the complexity of their interactions.
{"title":"The Role of Neighborhood Characteristics in Late Stage Melanoma Diagnosis among Hispanic Men in California, Texas, and Florida, 1996-2012.","authors":"Valerie M Harvey, Clinton W Enos, Jarvis T Chen, Hadiza Galadima, Karl Eschbach","doi":"10.1155/2017/8418904","DOIUrl":"https://doi.org/10.1155/2017/8418904","url":null,"abstract":"<p><strong>Background: </strong>Hispanics diagnosed with cutaneous melanoma are more likely to present at advanced stages but the reasons for this are unknown. We identify <i>census tracts</i> at high risk for late stage melanoma diagnosis (LSMD) and examine the contextual predictors of LSMD in California, Texas, and Florida.</p><p><strong>Methods: </strong>We conducted a cross-sectional study using geocoded state cancer registry data. Using hierarchical multilevel logistic regression models we estimated ORs and 95% confidence intervals for the impact of socioeconomic, Hispanic ethnic concentration, index of dissimilarity, and health resource availability measures on LSMD.</p><p><strong>Results: </strong>We identified 12,493 cases. In California, late stage cases were significantly more likely to reside within census tracts composed mostly of Hispanics and immigrants. In Texas, LSMD was associated with residence in areas of socioeconomic deprivation and a higher proportion of immigrants. In Florida, living in areas of low education attainment, high levels of poverty, and a high percentage of Hispanic residents was significantly associated with LSMD. Residential segregation did not independently affect LSMD.</p><p><strong>Conclusion: </strong>The influence of contextual predictors on LSMD varied in magnitude and strength by state, highlighting both the cosegregation of social adversity and poverty and the complexity of their interactions.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/8418904","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35163688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-01-23DOI: 10.1155/2017/4024580
Caitlin C Murphy, Hanna K Sanoff, Karyn B Stitzenberg, John A Baron, Jennifer L Lund, Robert S Sandler
Background and Aims. As a first step toward understanding the increasing incidence of colorectal cancer (CRC) in younger (age < 50) populations, we examined demographic, clinicopathologic, and socioeconomic characteristics and treatment receipt in a population-based sample of patients newly diagnosed with stages II and III CRC. Methods. Patients were sampled from the National Cancer Institute's Patterns of Care studies in 1990/91, 1995, 2000, 2005, and 2010 (n = 6, 862). Tumor characteristics and treatment data were obtained through medical record review and physician verification. We compared sociodemographic and clinicopathologic characteristics and treatment patterns of younger (age < 50) and older (age 50-69, age ≥ 70) CRC patients. Results. Younger patients were more likely to be black (13%) and Hispanic (15%) than patients aged 50-69 years (11% and 10%, resp.) and ≥70 years (7% each). A larger proportion of young white (41%) and Hispanic (33%) patients had rectal tumors, whereas tumors in the right colon were the most common in young black patients (39%). The majority of younger patients received chemotherapy and radiation therapy, although receipt of microsatellite instability testing was suboptimal (27%). Conclusion. Characteristics of patients diagnosed with young-onset CRC differ considerably by race/ethnicity, with a higher proportion of black and Hispanic patients diagnosed at the age of < 50 years.
{"title":"Patterns of Sociodemographic and Clinicopathologic Characteristics of Stages II and III Colorectal Cancer Patients by Age: Examining Potential Mechanisms of Young-Onset Disease.","authors":"Caitlin C Murphy, Hanna K Sanoff, Karyn B Stitzenberg, John A Baron, Jennifer L Lund, Robert S Sandler","doi":"10.1155/2017/4024580","DOIUrl":"https://doi.org/10.1155/2017/4024580","url":null,"abstract":"<p><p><i>Background and Aims.</i> As a first step toward understanding the increasing incidence of colorectal cancer (CRC) in younger (age < 50) populations, we examined demographic, clinicopathologic, and socioeconomic characteristics and treatment receipt in a population-based sample of patients newly diagnosed with stages II and III CRC. <i>Methods.</i> Patients were sampled from the National Cancer Institute's Patterns of Care studies in 1990/91, 1995, 2000, 2005, and 2010 (<i>n</i> = 6, 862). Tumor characteristics and treatment data were obtained through medical record review and physician verification. We compared sociodemographic and clinicopathologic characteristics and treatment patterns of younger (age < 50) and older (age 50-69, age ≥ 70) CRC patients. <i>Results.</i> Younger patients were more likely to be black (13%) and Hispanic (15%) than patients aged 50-69 years (11% and 10%, resp.) and ≥70 years (7% each). A larger proportion of young white (41%) and Hispanic (33%) patients had rectal tumors, whereas tumors in the right colon were the most common in young black patients (39%). The majority of younger patients received chemotherapy and radiation therapy, although receipt of microsatellite instability testing was suboptimal (27%). <i>Conclusion.</i> Characteristics of patients diagnosed with young-onset CRC differ considerably by race/ethnicity, with a higher proportion of black and Hispanic patients diagnosed at the age of < 50 years.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2017/4024580","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34765710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-01-01Epub Date: 2017-09-13DOI: 10.1155/2017/6091709
Chelsea Anderson, Aaron N Winn, Stacie B Dusetzina, Hazel B Nichols
Background: Although treatment of ductal carcinoma in situ (DCIS) is controversial, national guidelines recommend considering endocrine therapy for women with estrogen receptor- (ER-) positive DCIS or those undergoing breast conserving surgery (BCS) without radiation. We evaluated uptake and predictors of endocrine therapy use among older women with DCIS.
Methods: In the SEER-Medicare database, we identified women aged 65+ years diagnosed with DCIS during 2007-2011. We evaluated demographic, tumor, and treatment characteristics associated with endocrine therapy initiation.
Results: Among 2,945 women with DCIS, 41% initiated endocrine therapy (66% tamoxifen, 34% aromatase inhibitors). Initiation was more common among women with ER-positive than ER-negative DCIS (48% versus 16%; HR = 3.75, 95% CI: 2.91-4.83); 28% of women with unknown ER status initiated endocrine therapy. Initiation was less common after BCS alone compared to BCS with radiation (32% versus 50%; HR = 0.69, 95% CI: 0.59-0.80).
Conclusions: Less than half of older women with DCIS initiate endocrine therapy to prevent second breast cancers. Our findings suggest use was more common, but not exclusive, among women with ER-positive DCIS, but not among women who underwent BCS alone. Endocrine therapy should be targeted toward patients most likely to benefit from its use.
{"title":"Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ.","authors":"Chelsea Anderson, Aaron N Winn, Stacie B Dusetzina, Hazel B Nichols","doi":"10.1155/2017/6091709","DOIUrl":"10.1155/2017/6091709","url":null,"abstract":"<p><strong>Background: </strong>Although treatment of ductal carcinoma in situ (DCIS) is controversial, national guidelines recommend considering endocrine therapy for women with estrogen receptor- (ER-) positive DCIS or those undergoing breast conserving surgery (BCS) without radiation. We evaluated uptake and predictors of endocrine therapy use among older women with DCIS.</p><p><strong>Methods: </strong>In the SEER-Medicare database, we identified women aged 65+ years diagnosed with DCIS during 2007-2011. We evaluated demographic, tumor, and treatment characteristics associated with endocrine therapy initiation.</p><p><strong>Results: </strong>Among 2,945 women with DCIS, 41% initiated endocrine therapy (66% tamoxifen, 34% aromatase inhibitors). Initiation was more common among women with ER-positive than ER-negative DCIS (48% versus 16%; HR = 3.75, 95% CI: 2.91-4.83); 28% of women with unknown ER status initiated endocrine therapy. Initiation was less common after BCS alone compared to BCS with radiation (32% versus 50%; HR = 0.69, 95% CI: 0.59-0.80).</p><p><strong>Conclusions: </strong>Less than half of older women with DCIS initiate endocrine therapy to prevent second breast cancers. Our findings suggest use was more common, but not exclusive, among women with ER-positive DCIS, but not among women who underwent BCS alone. Endocrine therapy should be targeted toward patients most likely to benefit from its use.</p>","PeriodicalId":15366,"journal":{"name":"Journal of Cancer Epidemiology","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2017-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5615957/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35472858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}